Claudio Laudani/X
Aug 8, 2025, 15:28
Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on X:
”The landscape of antiplatelets has changed in the last decade, shifting from the initial focus on long-term DAPT to P2Y12 inhibitor monotherapy. In this review, we summarize the pharmacology and clinical evidence on antiplatelet montherapy.”
Read the full article here.
Title: Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention
Authors: Claudio Laudani, Daniele Giacoppo, Antonio Greco, Luis Ortega-Paz, Georges El Khoury, Davide Capodanno, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar
-
Aug 12, 2026, 05:35Burjor Langdana: Why Does Blast Traumatised Facial Tissue Keep Swelling and often Heal Badly